Affymetrix and OGT settle lawsuits

25 March 2001

Affymetrix of the USA and the UK's Oxford Gene Technology have settledall existing litigation between the two firms, which resulted from a dispute of ownership of technologies (Marketletters passim). Edwin Southern, OGT's chairman, said that "it is essential for genomic research that these matters have been resolved," adding that the firm can concentrate on its main objectives "of developing its own technology and business and licensing others to do the same." Financial details of the settlement were not disclosed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight